Pharma channel feed – Endpoints News

Pharma channel feed

Bioverativ inks $100M gene therapy deal with Oxford BioMedica

8 years ago

After a slapdown on Orkambi price, Vertex is dropping French trial sites while warning patients on access

8 years ago

Woeful Axovant starts axing staff, but departing CEO David Hung gets a $2.6M exit package/bonus

8 years ago

FDA's Gottlieb outlines new goals in budget plan, looking to spur drug reviews

8 years ago

J&J wins snap approval of apalutamide, the first drug OK'd for nonmetastatic prostate cancer

8 years ago

Senior Merck chemist charged with risking catastrophe after pouring cyanide into Pennsylvania stormwater drain

8 years ago

Switzerland's Ferring Pharma to build $32M discovery, development and manufacturing center at HQ

8 years ago

What does biotech think about ‘right-to-try'? It might surprise you

8 years ago

Bristol-Myers lassos the next big thing in I/O, grabs '214 rights in a record $3.6B deal with Nektar

8 years ago

Novartis, Momenta grab a delayed FDA OK for blockbuster Copaxone knockoff

8 years ago

On a roll, Vertex grabs FDA OK for CF double shot Symdeko — prices at $292,000

8 years ago

Taking on a big challenge, ex-Celgene CEO Bob Hugin readies a run for the Senate

8 years ago

What's the trouble with pain? Analysis shows scarce investments, high failure rate for new drugs

8 years ago

Once rejected, FDA now rolls out a short red carpet for Amicus’ migalastat

8 years ago

What's he thinking about? Vivek Ramaswamy lines up a heavyweight title fight for a late-stage diabetes drug

8 years ago

Market crash slumps biotech as investors yank $1.2B from funds

8 years ago

Seattle Genetics seeds a new immuno-oncology collaboration with the protein explorers at Pieris

8 years ago

In latest blow to Teva, CGRP migraine med could be delayed while rivals race towards the finish line

8 years ago

Gilead gets a blockbuster boost from an FDA OK of HIV triplet Biktarvy — and rival GSK fires back

8 years ago

Verastem takes AbbVie’s blood cancer castoff to the FDA

8 years ago

J&J antes up on a $1B gamble that Theravance has the next blockbuster JAK for Crohn’s, ulcerative colitis

8 years ago

Zogenix wins inside track at FDA with childhood epilepsy ‘breakthrough’

8 years ago

The Endpoints 100: Biotech execs stampede into 2018 with a cheer for the FDA and bullish feelings on public markets, private investors and a ‘hot’ M&A future

8 years ago

Slammed by a trial hold, Intarcia terminates studies and axes staff in wake of an FDA rejection

8 years ago

First page Previous page 307 308 309310311 312 313 Next page Last page